NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT02017860 2020-04-30
Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Novartis
Phase 2 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00985374 2016-11-02
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT02450175 2015-05-21
Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls
Sinai Hospital of Baltimore
Phase NA Unknown
NCT01096199 2014-01-22
A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)
National University Hospital, Singapore
Phase 1 Terminated
NCT00496600 2012-06-14
Phase I Study of Patupilone and RAD001
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT00903188 2009-05-18
CISTCERT
University Hospital, Antwerp
Phase 4 Unknown